Clinical Technology Advisors Chosen as North American and European Distributor of the SIMpill Medication Compliance System
Clinical Technology Advisors, Inc. (CTA), a contract business development and support services organization focused on assisting emerging technology companies with their entry and progression into the clinical trials industry, and SIMpill (Pty), a leader in the area of wireless medication compliance technologies, have entered into a Distribution and Services Agreement allowing CTA to sell the SIMpill wireless pill bottle and associated medication compliance services to the biopharmaceutical industry in North America and Europe.
ACTON, Mass. and CAPE TOWN, South Africa, May 2, 2005 --Clinical Technology Advisors, Inc. (CTA), a contract business development and support services organization focused on assisting emerging technology companies with their entry and progression into the clinical trials industry, and SIMpill (Pty), a leader in the area of wireless medication compliance technologies, have entered into a Distribution and Services Agreement allowing CTA to sell the SIMpill wireless pill bottle and associated medication compliance services to the biopharmaceutical industry in North America and Europe. The focus of this Agreement is to offer the biopharmaceutical industry a device that can track and manage real-time medication compliance during clinical trials.
"There have been some sincere attempts to address the issue of medication compliance in a clinical trial environment, but none have the immediacy of the SIMpill wireless solution," stated Dave Rosa, President and Chief Advisor of CTA. "The ability to have a research subject contacted on their cell phone or similar device if they miss a scheduled medication dose is a powerful enforcement tool to ensure that the subjects stay on track with their medication."
"We are very excited to have the resources that CTA brings to our overall strategy to be the leader in producing the most innovative medication compliance devices to address this crucial issue," added Dr. David Green, President of SIMpill. "In South Africa, we have been successfully using the solution to monitor medication compliance in severe diseases such as HIV infection and tuberculosis. I am confident that the solution will add another level of scientific rigor to the clinical trials process."
The SIMpill medication compliance system consists of a standard pill bottle attached to a device that contains the equivalent of a GSM/GPRS wireless phone. The device is programmed with "time tolerances" based upon the dosing schedule of the drug being tested. The bottle sends an SMS message to a central server once the subject opens the bottle. If this message is not received within the time tolerance programmed into the system, an outgoing message is then sent to the subject's cell phone reminding them to take their medication. If the bottle is still not opened within the secondary time tolerance, then a message (SMS, email, or fax) can be sent to a caregiver or investigational site personnel.
CTA will be exhibiting (Booth T-3) at the upcoming International Society for Pharmaceutical Outcomes Research (ISPOR) 10th Annual Meeting in Washington, DC, on May 16th and 17th. The SIMpill device will be available for hands-on evaluation.
About Clinical Technology Advisors, Inc (CTA):
CTA (www.clintechadvisors.com) employs a unique model of providing emerging technology companies with contract business development staff as they introduce or enhance their products and services within the clinical trials industry. CTA also provides study set-up, data management, and field support services to assist pharmaceutical, biotechnology, medical device, and nutraceutical companies with the utilization of technology solutions to expedite data collection during their clinical trials.
About SIMpill (Pty):
SIMpill (www.simpill.com) is a leader in providing innovative, proven, affordable and usable solutions to enable health organizations to be more efficient and effective. Our primary focus is the use of wireless technologies to support patients with chronic conditions to take their medication as prescribed.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
